Activities

VFI develops a range of adjuvants and provides expertise for the optimisation of vaccine formulations suitable for preclinical and clinical testing.

SWE adjuvant in open-access for clinical use

Sepivac SWE™  is VFI’s first adjuvant to reach clinical testing and is now available under GMP grade for the benefit of the whole vaccine community.

Working with you

Industry

Catalyzing access to adjuvant and formulation expertise

Contact us to discuss your projects